Welcome to this comprehensive guide on Pulmonary Diseases: Diagnosis and Treatment, designed especially for students. Understanding respiratory conditions is crucial in healthcare, and this article breaks down complex topics like COPD, asthma, interstitial lung diseases, and more, offering clear insights into their recognition and management. We'll cover everything from common symptoms to advanced diagnostic techniques and therapeutic approaches, ensuring you grasp the essentials for your studies and future practice.

Pulmonary Diseases: An Overview for Students

Pulmonary diseases encompass a wide range of conditions affecting the lungs and respiratory system, leading to various symptoms such as shortness of breath, cough, and chest pain. These diseases can significantly impact a patient's quality of life and often require precise diagnosis and tailored treatment plans. This article will delve into the two main categories: obstructive and restrictive lung diseases, along with other significant pulmonary conditions.

Obstructive Lung Diseases: Diagnosis and Treatment

Obstructive lung diseases are characterized by airflow obstruction, making it difficult to exhale air from the lungs. Key examples include Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Chronic Obstructive Pulmonary Disease (COPD) Explained

COPD is a leading cause of death, primarily characterized by chronic bronchitis and emphysema, which often coexist. It is defined as chronic cough productive of sputum for at least 3 months per year for at least 2 consecutive years (chronic bronchitis), or permanent enlargement of air spaces due to destruction of alveolar walls (emphysema).

Risk Factors and Pathogenesis of COPD:

Tobacco smoke is the primary cause, accounting for almost 90% of cases. The rate of FEV1 decline is significantly faster in smokers.
Alpha-1 antitrypsin deficiency increases risk, especially with smoking.
Environmental factors like secondhand smoke, fumes, or dust.
Chronic asthma-COPD overlap syndrome.
Pathogenesis involves excess mucus production, inflammation, scarring, and destruction of alveolar walls due to an imbalance of proteases and antiproteases, worsened by tobacco smoke.

Clinical Features of COPD:

Symptoms include cough, sputum production, and dyspnea, often starting with exertional dyspnea.
Signs may include prolonged expiratory time with pursed-lip breathing, end-expiratory wheezes, decreased breath sounds, hyperresonance, and distant heart sounds.
Severe COPD signs: tachypnea, tachycardia, cyanosis, accessory muscle use, and tripod position.
Patients with predominant emphysema (often called "Pink Puffers") tend to be thin with a barrel chest and tachypnea. Those with predominant chronic bronchitis ("Blue Bloaters") are often overweight and cyanotic with chronic cough and sputum production.

Diagnosing COPD:

Pulmonary Function Tests (PFTs), specifically spirometry, are the definitive diagnostic test. They show an obstructive pattern: decreased FEV1 and an FEV1/FVC ratio <0.70.
TLC and residual volume are increased, indicating air trapping. FEV1 staging guides disease severity (e.g., FEV1
Smoking cessation is the most critical intervention, slowing disease progression and improving symptoms.
Inhaled bronchodilators: Short-acting (SAMA, SABA) and long-acting (LAMA, LABA) antimuscarinics and beta-2 agonists are first-line. Combinations can be more effective and improve adherence.
Inhaled corticosteroids (ICS) are typically used in combination with long-acting bronchodilators for patients with significant symptoms or frequent exacerbations, especially those with serum eosinophils >300 cells/μL.
Theophylline (oral) and phosphodiesterase-4 inhibitors (e.g., roflumilast) may be considered for refractory cases or to reduce exacerbations.
Oxygen therapy improves survival and quality of life in patients with chronic hypoxemia and complications like pulmonary hypertension and cor pulmonale. Criteria for long-term oxygen therapy include PaO2 ≤ 55 mm Hg or O2 saturation ≤ 88% at rest or during exercise.
Pulmonary rehabilitation improves exercise tolerance, functional status, and quality of life.
Vaccinations against influenza and Streptococcus pneumoniae are crucial.
Surgery (lung volume reduction or transplantation) may be beneficial in selected patients.

Acute COPD Exacerbation Treatment:

Bronchodilators (beta-2 agonists alone or with antimuscarinics) are first-line.
Systemic corticosteroids (e.g., oral prednisone) are used for patients requiring hospitalization.
Antibiotics (azithromycin, doxycycline, fluoroquinolones) are reserved for moderate to severe exacerbations, often triggered by pulmonary infections (viruses, S. pneumoniae, H. influenzae, Mycoplasma pneumoniae, Moraxella catarrhalis).
Supplemental oxygen targeting 88% to 92% saturation. Be aware of CO2 retention risk if saturation is >92%.
Noninvasive positive pressure ventilation (NPPV, BiPAP, CPAP) may decrease the need for invasive mechanical ventilation.
Intubation and mechanical ventilation may be required if the patient deteriorates (increasing RR, PaCO2, worsening acidosis).

Complications of COPD:

Acute exacerbations (often due to infection, nonadherence, cardiac disease).
Secondary polycythemia (compensatory response to chronic hypoxemia).
Pulmonary hypertension and cor pulmonale in severe, long-standing disease.

Asthma: Understanding a Common Obstructive Disease

Asthma is characterized by a triad of airway inflammation, airway hyperresponsiveness, and reversible airflow obstruction. It can begin at any age, triggered by various factors.

Types and Triggers of Asthma:

Extrinsic asthma (most cases): Patients are atopic, producing IgE to environmental antigens, often associated with eczema and hay fever.
Intrinsic asthma: Not related to atopy or environmental triggers.
Triggers: Aeroallergens (pollens, dust mites), irritants (tobacco smoke, fumes), cold air, exercise, viral infections, and certain medications (beta-blockers, aspirin).

Clinical Features of Asthma:

Intermittent symptoms: shortness of breath, wheezing, chest tightness, and cough, varying in severity and typically worse at night or after trigger exposure.
Wheezing, commonly expiratory, is a hallmark physical finding.
Signs of acute severe asthma: tachypnea, diaphoresis, speaking in incomplete sentences, accessory muscle use, and paradoxical movement of abdomen/diaphragm (sign of impending respiratory failure).

Diagnosing Asthma:

PFTs are required for diagnosis, showing an obstructive pattern (decreased FEV1, decreased FEV1/FVC ratio <0.70).
Spirometry before and after bronchodilators confirms reversible airway obstruction: an increase in FEV1 or FVC by at least 12% after bronchodilator inhalation.
Bronchoprovocation test (e.g., methacholine challenge) is used when asthma is suspected but PFTs are nondiagnostic. Hyperresponsive airways show >20% decrease in FEV1 with methacholine.
Peak flow monitoring is useful for self-monitoring and adjusting inhaled steroid doses based on asthma severity.

Treating Asthma:

Inhaled Beta-2 Agonists (SABA, LABA): SABAs (e.g., albuterol) are rescue medications for acute attacks. LABAs (e.g., salmeterol) are used with ICS for severe/persistent symptoms.
Inhaled Corticosteroids (ICS): Preferred for moderate to severe asthma, decreasing hyperresponsiveness and exacerbation frequency. Oral steroids are reserved for severe, persistent asthma.
Montelukast (leukotriene modifiers): May be useful for prophylaxis of mild exercise-induced asthma and control of moderate persistent disease.
Theophylline: Can be an add-on to ICS for persistent symptoms.
Treatment guidelines are stepwise, based on severity (intermittent vs. persistent; mild, moderate, or severe).

Acute Severe Asthma Exacerbation Treatment (Hospital Admission):

Inhaled beta-2 agonist (first-line therapy, via nebulizer or MDI with spacer).
Corticosteroids (IV or oral), tapered upon clinical improvement. ICS initiated during tapering.
Third-line: IV magnesium for severe exacerbations unresponsive to initial therapies.
Supplemental oxygen (maintain saturation >90%).
Antibiotics only if bacterial pneumonia is suspected.
Intubation for respiratory failure or impending failure.

Complications of Asthma:

Status asthmaticus (unresponsive to standard medications).
Acute respiratory failure (due to respiratory muscle fatigue).
Pneumothorax, atelectasis, pneumomediastinum.

Bronchiectasis: Diagnosis and Treatment Approaches

Bronchiectasis involves permanent, abnormal dilation and destruction of bronchial walls with chronic inflammation and impaired secretion clearance.

Causes of Bronchiectasis:

Recurrent infections (airway obstruction, immunodeficiency, allergic bronchopulmonary aspergillosis, mycobacterium).
Cystic fibrosis (most common cause, accounting for half of cases).
Primary ciliary dyskinesia (e.g., Kartagener syndrome).
Autoimmune diseases (rheumatoid arthritis, lupus, Crohn's disease).

Clinical Features of Bronchiectasis:

Chronic cough with large amounts of mucopurulent, foul-smelling sputum.
Dyspnea, hemoptysis (usually mild).
Recurrent or persistent pneumonia.

Diagnosing Bronchiectasis:

High-resolution CT (HRCT) scan is the diagnostic study of choice, showing airway dilatation.
PFTs typically reveal an obstructive pattern.
CXR is often abnormal but nonspecific.

Treating Bronchiectasis:

Antibiotics for acute exacerbations, guided by sputum microbiology.
Bronchial hygiene: hydration, chest physiotherapy (postural drainage, chest percussion).
Inhaled bronchodilators.
Main goal is to prevent pneumonia and hemoptysis.

Cystic Fibrosis: A Brief Overview

Cystic fibrosis (CF) is an autosomal recessive condition causing defective chloride and water transport, leading to excessively thick secretions. This results in obstructive lung disease with chronic pulmonary infections (often Pseudomonas), pancreatic insufficiency, and other GI/GU complications. Treatment includes pancreatic enzyme replacement, fat-soluble vitamin supplements, chest physical therapy, vaccinations, antibiotics for infections, and inhaled recombinant human deoxyribonuclease (DNase).

Interstitial Lung Diseases (ILD): Diagnosis and Management

ILDs are a diverse group of inflammatory processes affecting the alveolar walls, leading to fibrosis, architectural distortion, and impaired gas exchange.

General Characteristics of ILD:

Involves inflammation, fibroelastic proliferation, and collagen deposition, potentially leading to irreversible fibrosis.
Prognosis is highly variable.
Patients with environmental/occupational exposure (e.g., asbestosis) may pursue lawsuits.

Clinical Features of ILD:

Symptoms: Dyspnea (initially exertional, then at rest), nonproductive cough, fatigue.
Signs: Dry "velcro-like" crackles at lung bases, digital clubbing (especially in idiopathic pulmonary fibrosis), signs of pulmonary hypertension/cor pulmonale in advanced disease, cyanosis.

Diagnosing ILD:

CXR: Nonspecific diffuse changes (reticular, ground glass, honeycombing).
HRCT scan: Best for showing extent of fibrosis (bibasilar reticular opacities, honeycombing, traction bronchiectasis).
PFTs show a restrictive pattern: low lung volumes (FEV1, FVC, TLC), normal or increased FEV1/FVC ratio, and low diffusing capacity (DLCO).
Oxygen desaturation during exercise.
Tissue biopsy may be required if diagnosis is unclear from HRCT and PFTs.

Specific Types of Interstitial Lung Diseases

Sarcoidosis: A chronic systemic granulomatous disease with noncaseating granulomas, almost always involving the lungs. Bilateral hilar adenopathy is a hallmark. Diagnosis relies on clinical, radiographic, and histologic findings. Most cases resolve spontaneously; systemic corticosteroids are the treatment of choice for symptomatic patients or those with organ involvement.
Pulmonary Langerhans Cell Histiocytosis (PLCH): Rare interstitial pneumonia often linked to cigarette smoking, showing cystic lesions on CT. Smoking cessation is crucial.
Granulomatosis With Polyangiitis (GPA): Necrotizing granulomatous vasculitis affecting vessels of lungs, kidneys, and upper airway. Tissue biopsy is gold standard; c-ANCA positive. Treated with glucocorticoids and immunosuppressants.
Eosinophilic Granulomatosis With Polyangiitis (EGPA): Granulomatous vasculitis in asthmatics, presenting with pulmonary infiltrates, rash, and eosinophilia. Associated with p-ANCA. Treated with systemic glucocorticoids.

Environmental Lung Diseases (Pneumoconiosis):

Coal Worker's Pneumoconiosis: Caused by coal dust inhalation, leading to fibrosis.
Asbestosis: Diffuse interstitial fibrosis from asbestos fibers, predilection for lower lobes, increased risk of bronchogenic carcinoma and malignant mesothelioma. CXR shows pleural plaques, HRCT shows honeycombing.
Silicosis: Nodular peribronchial fibrosis (upper lobes), increased risk of TB. Sources include mining and sandblasting.
Berylliosis: Acute or chronic forms, with chronic disease similar to sarcoidosis. Beryllium lymphocyte proliferation test is diagnostic.

Interstitial Lung Disease Associated With Hypersensitivity:

Hypersensitivity Pneumonitis: Immune-mediated pneumonitis from inhaling antigenic agents (e.g., moldy hay, bird droppings). Acute form has flu-like features; chronic form leads to restrictive lung disease. Treatment involves removing the offending agent and sometimes glucocorticoids.
Eosinophilic Pneumonia: Fever, peripheral eosinophilia, and peripheral pulmonary infiltrates on CXR. Glucocorticoids are usually very effective.

Alveolar Filling Disease:

Anti-GBM Antibody or Goodpasture Disease: Autoimmune disease with IgG antibodies against glomerular and alveolar basement membranes, causing hemorrhagic pneumonitis and glomerulonephritis. Poor prognosis, treated with plasmapheresis, cyclophosphamide, and corticosteroids.
Pulmonary Alveolar Proteinosis (PAP): Accumulation of surfactant-like protein in alveoli. Dry cough, dyspnea, ground-glass appearance on CXR/CT. Lung lavage is treatment.

Miscellaneous Interstitial Lung Diseases:

Idiopathic Pulmonary Fibrosis (IPF): Unknown etiology, more common in older men smokers, progressive dyspnea and nonproductive cough. Mean survival 3-7 years. HRCT shows honeycombing. Antifibrotic agents (nintedanib, pirfenidone) can slow progression.
Cryptogenic Organizing Pneumonitis (COP): Inflammatory lung disease mimicking pneumonia, often idiopathic. Responds well to corticosteroids.
Radiation Pneumonitis: Interstitial pulmonary inflammation post-thoracic irradiation. Features include low-grade fever, cough, dyspnea. CT scan is best study. Corticosteroids for symptomatic patients.

Other Significant Pulmonary Conditions

Beyond obstructive and interstitial diseases, several other conditions affect the pulmonary system, requiring distinct diagnostic and treatment approaches.

Pleural Effusion: Diagnosis and Treatment Strategies

A pleural effusion is fluid in the pleural space, caused by increased fluid drainage or production, or decreased lymphatic drainage.

Types and Causes of Pleural Effusions:

Transudative effusions: Due to elevated capillary pressure (e.g., Congestive heart failure) or decreased plasma oncotic pressure (e.g., hypoalbuminemia). Other causes include cirrhosis, pulmonary embolism (PE), nephrotic syndrome, atelectasis.
Exudative effusions: Caused by increased permeability of pleural surfaces or decreased lymphatic flow due to damage (e.g., bacterial pneumonia, TB, malignancy, viral infection, PE, collagen vascular diseases). Meet at least one of Light's criteria (e.g., pleural protein/serum protein >0.5).

Clinical Features of Pleural Effusion:

Often asymptomatic, but can cause dyspnea on exertion, peripheral edema, orthopnea, paroxysmal nocturnal dyspnea.
Signs: Dullness to percussion, decreased breath sounds, and decreased tactile fremitus over the effusion.

Diagnosing Pleural Effusion:

CXR (PA and lateral): Blunting of costophrenic angle (requires ~250 mL fluid). Lateral decubitus films are more reliable for small effusions.
Point-of-care ultrasound or CT chest: More reliable for detecting small effusions.
Thoracentesis is indicated for evaluation of all new pleural effusions; provides diagnostic and therapeutic relief. Complication: pneumothorax (10-15%).

Treating Pleural Effusion:

Transudative: Diuretics, sodium restriction, therapeutic thoracentesis for massive effusions.
Exudative: Treat underlying disease.
Parapneumonic effusions:
Uncomplicated: Antibiotics alone.
Complicated/Empyema: Chest tube drainage, intrapleural fibrinolytic agents (e.g., tPA), surgical lysis of adhesions.

Empyema: Diagnosis and Treatment

Empyema is pus within the pleural space, typically a complication of bacterial pneumonia or other infections.

Clinical Features: Those of the underlying disease (most commonly pneumonia).
Diagnosis: CXR and CT scan of the chest.
Treatment: Aggressive drainage (thoracentesis, chest tube) and appropriate antibiotic therapy. Recurrence is common.

Pneumothorax: Understanding Air in the Pleural Space

Pneumothorax is air in the normally airless pleural space, leading to lung collapse.

Categories of Pneumothorax:

Spontaneous Pneumothorax:
Primary spontaneous pneumothorax: Occurs in healthy individuals due to rupture of subpleural blebs. More common in tall, lean young men. Usually resolves spontaneously.
Secondary spontaneous pneumothorax: Complication of underlying lung disease (COPD, asthma, ILD, CF, TB). More life-threatening due to lack of pulmonary reserve; often requires definitive intervention (e.g., pleurodesis) to prevent recurrence.
Traumatic Pneumothorax: Often iatrogenic (e.g., central line placement).

Clinical Features of Pneumothorax:

Symptoms: Ipsilateral chest pain (sudden), dyspnea, cough.
Signs: Decreased breath sounds, hyperresonance, decreased/absent tactile fremitus on affected side. Mediastinal shift toward pneumothorax side.

Diagnosing Pneumothorax:

CXR confirms diagnosis in stable patients, showing the visceral pleural line.
Pleural ultrasound for rapid bedside evaluation (unstable patients) shows lack of lung sliding.

Treating Pneumothorax:

Primary spontaneous:
Small, asymptomatic: Observation (resolves in ~10 days), or small chest tube.
Larger/symptomatic: Supplemental oxygen, needle aspiration or chest tube insertion.
Secondary spontaneous: Chest tube drainage.

Tension Pneumothorax: A Medical Emergency

A tension pneumothorax is a life-threatening condition where air accumulates under positive pressure in the pleural space, collapsing the ipsilateral lung and shifting the mediastinum away from the affected side.

Causes: Mechanical ventilation with barotrauma, CPR, trauma.
Clinical Features: Hypotension (impaired cardiac filling), distended neck veins, tracheal shift away from affected side, decreased breath sounds, hyperresonance to percussion.
Treatment: Medical emergency! Immediate chest decompression with a large-bore needle, followed by chest tube placement. Do not delay for CXR if suspected.

Lung Neoplasms: Understanding Lung Cancer

Lung cancer is broadly divided into small cell lung cancer (SCLC, 15%) and non-small cell lung cancer (NSCLC, 85%).

Risk Factors for Lung Cancer:

Cigarette smoking accounts for >85% of cases.
Second-hand smoke, asbestos exposure (synergistic with smoking), radon, COPD (independent risk factor).

Clinical Features of Lung Cancer:

Generally nonspecific; often widespread by the time symptoms appear.
Local manifestations: Cough, hemoptysis, obstruction, wheezing, dyspnea, recurrent pneumonia.
Constitutional symptoms: Anorexia, weight loss, weakness (usually advanced disease).
Local invasion syndromes:
Superior vena cava (SVC) syndrome: Obstruction of SVC, facial/arm edema, dilated chest veins, JVD. More common with SCLC.
Phrenic nerve palsy: Hemidiaphragmatic paralysis.
Recurrent laryngeal nerve palsy: Hoarseness.
Horner syndrome: Unilateral facial anhidrosis, ptosis, miosis (apical tumor).
Pancoast tumor: Superior sulcus tumor involving C8, T1-T2 nerve roots, causing shoulder pain, upper extremity weakness, often with Horner syndrome.
Malignant pleural effusion, metastatic disease (brain, bone, adrenals, liver).
Paraneoplastic syndromes: SIADH, Cushing syndrome (both with SCLC), hypercalcemia (squamous cell), hypertrophic pulmonary osteoarthropathy, Eaton-Lambert syndrome (SCLC).

Diagnosing Lung Cancer:

CXR: Abnormal findings in nearly all patients. Stability over 2 years suggests benign lesion.
CT scan of chest with IV contrast: Useful for staging and detecting metastases.
Bronchoscopy with EBUS-TBNA: First-choice for central lesions and lymph nodes.
Whole-body PET: Provides additional staging information.
Transthoracic needle biopsy: For peripheral lesions.
Mediastinoscopy: For direct visualization of superior mediastinum.
Cytologic examination of sputum (low yield).
Crucial: Tissue biopsy is necessary to differentiate SCLC from NSCLC for treatment planning.

Treating Lung Cancer:

NSCLC: Surgery for limited disease is the best option. Radiation therapy is an adjunct. Chemotherapy (including immunotherapies) may show modest survival benefits.
SCLC: Often extensive at presentation. Systemic chemotherapy is the mainstay. For limited disease, chemotherapy + radiation. Prophylactic whole-brain irradiation for responders to decrease brain metastases. Surgery has limited role.

Solitary Pulmonary Nodule (SPN): Evaluation

An SPN is a single, well-circumscribed nodule, often discovered incidentally. The main concern is malignancy.

Factors Favoring Malignancy:

Age >50, smoking history, nodule size >10 mm, irregular borders, subsolid attenuation (ground-glass), eccentric/stippled calcification, steady growth over serial imaging.

Factors Favoring Benign Diagnosis:

Age <50, nonsmoker, nodule size <5 mm, no growth over 2 years, circular/regular shape, central/laminated/popcorn calcification, solid nodule.

Management based on probability:

Low-probability: Serial CT scan.
Intermediate-probability (≥1 cm): PET scan; if positive, biopsy.
High-probability: Biopsy (transbronchial, transthoracic, VATS) followed by lobectomy if appropriate.

Acute Respiratory Failure: Causes and Management

Acute respiratory failure occurs when there is inadequate oxygenation (hypoxia: PaO2 <60 mm Hg) or inadequate ventilation (hypercapnia: PaCO2 >50 mm Hg) or both.

Causes of Respiratory Failure:

CNS depression/insult (drug overdose, stroke).
Neuromuscular diseases (myasthenia gravis, GBS).
Upper airway obstruction.
Thorax and pleura issues (kyphoscoliosis, pneumothorax).
Cardiovascular system/blood issues (CHF, PE, anemia).
Lower airways/alveoli diseases (asthma, COPD, pneumonia, ARDS, pulmonary edema).

Classification of Acute Respiratory Failure:

Hypoxemic respiratory failure: Low PaO2 with low/normal PaCO2. Caused by lung diseases (ARDS, pneumonia, pulmonary edema). Mechanisms: V/Q mismatch and intrapulmonary shunting. Responsive to supplemental oxygen (V/Q mismatch), but not shunting.
Hypercapnic (hypercarbic) respiratory failure: Failure of alveolar ventilation, leading to CO2 retention and hypoxemia. Caused by underlying lung disease (COPD, asthma, CF) or impaired ventilation (neuromuscular, CNS depression, respiratory fatigue).

Clinical Features of Acute Respiratory Failure:

Symptoms: Dyspnea (first symptom), cough (variable).
Signs: Inability to speak in complete sentences, accessory muscle use, tachypnea, tachycardia, cyanosis, impaired mentation.

Diagnosing Acute Respiratory Failure:

ABG analysis confirms diagnosis and severity. Hypoxemia mechanisms: V/Q mismatch, shunting, diffusion limitation, hypoventilation. Hypercapnia: hypoventilation.

Managing Acute Respiratory Failure:

Treat underlying cause.
Maintain patent airway.
Supplemental oxygen.
Mechanical ventilation if other measures fail. Modes include Assist-Control (AC), Synchronized Intermittent Mandatory Ventilation (SIMV), CPAP, Pressure Support Ventilation (PSV), Noninvasive Mechanical Ventilation (NPPV: BiPAP/CPAP via mask).
Key parameters: Minute ventilation (RR x VT) affects PaCO2. FiO2 and PEEP affect PaO2.

Acute Respiratory Distress Syndrome (ARDS): A Critical Condition

ARDS is a severe form of acute respiratory failure characterized by bilateral pulmonary infiltrates and hypoxemia not explained by cardiac failure. It involves diffuse alveolar damage, increased capillary permeability, and surfactant dysfunction.

Causes: Sepsis (most common), aspiration of gastric contents, severe trauma, multiple transfusions, near drowning, acute pancreatitis, drug overdose, toxic inhalations, intracranial hypertension, cardiopulmonary bypass.
Clinical Features: Dyspnea, tachypnea, tachycardia. Progressive hypoxemia refractory to supplemental oxygen. Difficult to ventilate due to stiff, noncompliant lungs (high peak airway pressures).
Diagnosis: Berlin definition (2012): Hypoxemia (PaO2/FiO2 ratio
Supportive care is the mainstay: mechanical ventilation (low tidal volumes), PEEP, prone positioning, fluid management. No specific pharmacologic treatment. Goal is to maintain adequate oxygenation and ventilation while preventing ventilator-induced lung injury.

Pulmonary Hypertension (PH): Understanding High Blood Pressure in Lungs

PH is defined as a mean pulmonary arterial pressure >20 mm Hg at rest. It's classified into five groups based on etiology.

Classification (WHO System):
Group 1: Pulmonary Arterial Hypertension (PAH) – idiopathic, familial, connective tissue disorders, HIV, drugs.
Group 2: Left heart disease – secondary to left heart failure, valvular disease.
Group 3: Lung disease and/or chronic hypoxemia – ILD, COPD, OSA.
Group 4: Chronic thromboembolic disease – recurrent PE.
Group 5: Miscellaneous – vascular compression, sarcoidosis.
Clinical Features: Dyspnea on exertion (most common), fatigue, chest pain, syncope, peripheral edema. Signs may include narrow splitting and accentuation of P2, tricuspid regurgitation, jugular venous distention, hepatomegaly, ascites.
Diagnosis: Echocardiogram (estimates pulmonary artery pressure), right heart catheterization (confirms diagnosis and measures pressures), CXR, PFTs, ABGs, serology, V/Q scan (for Group 4).
Treatment: Goals are to improve symptoms and prolong life. General measures: oxygen for hypoxemia, diuretics for fluid overload, anticoagulation. Specific therapies depend on the PH group: endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues for Group 1 PAH. Treat underlying conditions for other groups (e.g., improve heart failure, manage lung disease).

Dyspnea: Assessing Shortness of Breath

Dyspnea, or shortness of breath, can be acute or chronic and is a common symptom in both heart and lung diseases.

Acute Dyspnea Causes: MI, heart failure, cardiac tamponade, bronchospasm, PE, pneumothorax, pneumonia, upper airway obstruction.
Chronic Dyspnea Causes: Asthma, COPD, ILD, heart disease, obesity, physical deconditioning.
Assessment: Evaluate baseline activity, onset, triggers (exertion, position), associated symptoms, and temporal progression. History of smoking, cough, sputum, infections, or occupational exposure suggests lung disease.

Frequently Asked Questions (FAQ) for Pulmonary Diseases

What are the main differences between obstructive and restrictive lung diseases?

Obstructive lung diseases (like asthma and COPD) involve difficulty exhaling air due to narrowed airways, leading to a decreased FEV1/FVC ratio. Restrictive lung diseases (like pulmonary fibrosis) involve reduced lung volumes due to stiffness or inability of the lungs to expand, leading to decreased FEV1 and FVC, but a normal or increased FEV1/FVC ratio.

How is asthma typically diagnosed in students?

Asthma diagnosis requires Pulmonary Function Tests (PFTs), specifically spirometry, which will show an obstructive pattern (decreased FEV1 and FEV1/FVC ratio). Reversibility is key: a significant increase in FEV1 or FVC after bronchodilator inhalation. If PFTs are normal but asthma is suspected, a bronchoprovocation test (e.g., methacholine challenge) can be used.

What are the most important lifestyle changes for managing COPD?

The single most important intervention for managing COPD is smoking cessation. Quitting smoking can significantly slow the decline in lung function and improve respiratory symptoms. Other crucial lifestyle changes include avoiding environmental irritants, regular exercise (as part of pulmonary rehabilitation), and getting recommended vaccinations (influenza and pneumococcal).

When should mechanical ventilation be considered for respiratory failure?

Mechanical ventilation is considered when other treatments fail to stabilize a patient in acute respiratory failure. Specific indications include increasing respiratory rate, increasing PaCO2, worsening acidosis, and persistent hypoxemia despite supplemental oxygen. For patients with COPD exacerbation, noninvasive positive pressure ventilation (NPPV) is often tried first to avoid invasive mechanical ventilation.

What are common signs and symptoms of lung cancer that students should be aware of?

Lung cancer symptoms are often non-specific and appear late. Common local manifestations include persistent cough, hemoptysis (coughing up blood), shortness of breath, wheezing, and recurrent pneumonia. Systemic symptoms like unexplained weight loss, anorexia, and weakness often indicate advanced disease. Specific syndromes like SVC syndrome, Horner syndrome, or Pancoast tumor can also arise from tumor invasion.

Pulmonary Diseases: Diagnosis and Treatment